Literature DB >> 27094385

Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia.

Wen-Sen Lee1, Po-Ren Hsueh2, Tai-Chin Hsieh1, Fu-Lun Chen1, Tsong-Yih Ou1, Shio-Shin Jean3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27094385     DOI： 10.1016/j.jmii.2016.03.008

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


× No keyword cloud information.
  8 in total

1.  In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.

Authors:  E M Aliouat; E Dei-Cas; N Gantois; M Pottier; C Pinçon; S Hawser; A Lier; D B Huang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-12       Impact factor: 3.267

2.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

3.  Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

Authors:  Di-Hong Yang; Yuan Xu; Lu Hong; Zhou-Ye Song; Wei-Hong Ge
Journal:  Respir Med Case Rep       Date:  2018-12-08

4.  Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.

Authors:  Q Tian; J Si; F Jiang; R Xu; B Wei; B Huang; Q Li; Z Jiang; T Zhao
Journal:  HIV Med       Date:  2020-12-04       Impact factor: 3.180

5.  Successful treatment of a kidney transplant patient with COVID-19 and late-onset Pneumocystis jirovecii pneumonia.

Authors:  Jing Peng; Ming Ni; Dunfeng Du; Yanjun Lu; Juan Song; Weiyong Liu; Na Shen; Xiong Wang; Yaowu Zhu; Bruce A Vallance; Ziyong Sun; Hong Bing Yu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-15       Impact factor: 3.944

6.  Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality.

Authors:  Yuqiong Wang; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan; Li Weng
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

7.  Pneumocystis jirovecii pneumonia in a patient receiving chemotherapy for advanced prostatic cancer: a case report.

Authors:  Chen Tiantian; Yan Jin; Zhang Jing; Feng Jing; Jin Xiaoyan
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

8.  Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study.

Authors:  Li Weng; Xu Huang; Lie Chen; Li-Qin Feng; Wei Jiang; Xiao-Yun Hu; Jin-Min Peng; Chun-Yao Wang; Qing-Yuan Zhan; Bin Du
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.